We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-16.09%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.65B
AUM Growth
-$1.07B
Cap. Flow
-$484M
Cap. Flow %
-29.24%
Top 10 Hldgs %
45.81%
Holding
77
New
–
Increased
10
Reduced
34
Closed
14

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$12.8M
2
COGT icon
Cogent Biosciences
COGT
+$6.35M
3
ESTA icon
Establishment Labs
ESTA
+$5.01M
4
ANNX icon
Annexon
ANNX
+$4.78M
5
ISRG icon
Intuitive Surgical
ISRG
+$4.1M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$83.3M
2
KRYS icon
Krystal Biotech
KRYS
+$81.8M
3
ABT icon
Abbott
ABT
+$29.8M
4
ALGN icon
Align Technology
ALGN
+$28.6M
5
FOLD
Amicus Therapeutics
FOLD
+$27.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
1
Krystal Biotech
KRYS
$10.4B
$188M 11.34%
1,021,078
-487,172
-32% -$81.8M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$105M 6.35%
10,595,089
-2,662,197
-20% -$27.3M
NRIX icon
3
Nurix Therapeutics
NRIX
$2.72B
$92.3M 5.58%
4,423,616
-59,400
-1% -$925K
STOK icon
4
Stoke Therapeutics
STOK
$2.04B
$63.8M 3.86%
4,721,054
-351,995
-7% -$4.75M
IMNM icon
5
Immunome
IMNM
$3.13B
$59.2M 3.58%
4,889,554
– –
RGNX icon
6
Regenxbio
RGNX
$638M
$53.5M 3.23%
4,569,802
+18,246
+0.4% +$284K
LIVN icon
7
LivaNova
LIVN
$4.43B
$51M 3.08%
929,506
-108,274
-10% -$6.17M
REPL icon
8
Replimune Group
REPL
$1.46B
$50.1M 3.03%
5,562,096
+1,832,113
+49% +$12.8M
ADCT icon
9
ADC Therapeutics
ADCT
$146M
$48.3M 2.92%
15,269,217
– –
KYMR icon
10
Kymera Therapeutics
KYMR
$9.82B
$47.1M 2.85%
1,579,275
-154,814
-9% -$5.36M
SRRK icon
11
Scholar Rock
SRRK
$7.04B
$45.4M 2.75%
5,453,083
-966,527
-15% -$11.8M
ZYME icon
12
Zymeworks
ZYME
$2.02B
$44.3M 2.68%
5,211,037
-349,761
-6% -$3.11M
FATE icon
13
Fate Therapeutics
FATE
$291M
$43.2M 2.61%
13,169,057
– –
COGT icon
14
Cogent Biosciences
COGT
$6.02B
$40.5M 2.45%
4,799,973
+837,371
+21% +$6.35M
BEAM icon
15
Beam Therapeutics
BEAM
$3.03B
$39.9M 2.41%
1,703,061
-176,556
-9% -$4.34M
SLN
16
Silence Therapeutics
SLN
$834M
$38.3M 2.31%
2,014,296
-13,373
-0.7% -$284K
AKRO
17
DELISTED
Akero Therapeutics
AKRO
$37.9M 2.29%
1,614,473
-244,229
-13% -$5.22M
BHVN icon
18
Biohaven
BHVN
$2.33B
$37.7M 2.28%
1,087,576
-75,665
-7% -$2.99M
NGNE icon
19
Neurogene
NGNE
$732M
$36.9M 2.23%
1,013,663
+78,411
+8% +$2.77M
PLRX icon
20
Pliant Therapeutics
PLRX
$68.7M
$34.5M 2.09%
3,209,591
+112,371
+4% +$1.45M
CTLT
21
DELISTED
CATALENT, INC.
CTLT
$33.5M 2.02%
595,570
-36,894
-6% -$2.06M
ANNX icon
22
Annexon
ANNX
$942M
$31.5M 1.9%
6,427,462
+924,272
+17% +$4.78M
BSX icon
23
Boston Scientific
BSX
$67.9B
$30.1M 1.82%
390,253
-170,673
-30% -$12.5M
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.87B
$26.7M 1.61%
759,516
-163,162
-18% -$6.46M
CLDX icon
25
Celldex Therapeutics
CLDX
$3.07B
$26.6M 1.61%
718,723
-177,731
-20% -$6.71M
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2024 Portfolio in Review

As of Q2 2024, Redmile Group held 77 positions worth $1.65B, down 39% from $2.72B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group withdrew a net $484M in Q2 2024, closing 14 positions and reducing 34 holdings. Its most notable exit was Deciphera Pharmaceuticals, Inc. Common Stock, an estimated $83.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group added an estimated $12.8M to Replimune Group.

  • Redmile Group added most to Replimune Group in Q2 2024, an estimated $12.8M increase.
  • Redmile Group's biggest Q2 2024 reduction was Krystal Biotech, cutting an estimated $81.8M.
  • Redmile Group fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2024, selling an estimated $83.3M.
  • Redmile Group's ten largest holdings make up 46% of its $1.65B portfolio in Q2 2024.
  • Redmile Group opened 0 new positions and closed 14 in Q2 2024.
  • Redmile Group's portfolio value fell 39% quarter-over-quarter to $1.65B.

Based on Redmile Group's 13F filing for Q2 2024, filed 14 Aug 2024.